WASHINGTON — The FDA approved the first mRNA-based flu vaccine in United States history on Tuesday, granting Moderna’s mFlusiva clearance for adults 50 and older, an advance that its manufacturer says is ready for this fall. Whether most older Americans can actually afford to get it is an entirely different question.
The Food and Drug Administration granted full approval to mFlusiva for adults between 50 and 64, and accelerated approval for adults 65 and older, a split that reflects lingering questions about how well the shot performs in the highest-risk group. In late-stage trials involving more than 40,000 older adults across 11 countries, mFlusiva demonstrated roughly 27 percent greater effectiveness against influenza than standard flu shots, NBC News reported. Moderna said the vaccine will be available for the 2026 flu season.
The distinction matters to patients because it matters to strain matching. Traditional flu vaccines require manufacturers to identify circulating strains roughly six months before each season, a timeline that frequently results in mismatches between the shot formulation and the strains actually spreading. mFlusiva’s mRNA platform compresses that window to two to three months, allowing Moderna to track circulating strains more closely before finalizing the product. The same manufacturing advantage earned mRNA flu vaccines a 9-to-0 federal advisory vote in June.
The path to approval was not linear. The FDA initially refused to review Moderna’s original application in early 2026, with Dr. Vinay Prasad, the agency’s top vaccine official, publicly criticizing the trial for lacking comparison data against a flu vaccine specifically recommended for adults 65 and older. Moderna revised its approach, splitting the application by age group and agreeing to conduct an additional post-approval study for the older cohort, CBS News reported. The agency reversed course and cleared the revised package.
A vaccine approved by the FDA and potentially unavailable at no cost to the patients who need it most is not a theoretical possibility this fall. It is the probable outcome. The ACIP, the federal body whose formal recommendations determine whether private insurers must cover vaccines under the Affordable Care Act, has been unable to hold a legally binding vote since a federal court blocked its reconstitution. Now in its seventh month, the ACIP quorum crisis means private insurers face no legal coverage obligation, and federal distribution programs including Vaccines for Children and Medicaid will not include mFlusiva until a recommendation is formally issued.
That regulatory gap did not arise independently. Health Secretary Robert F. Kennedy Jr., who previously called mRNA COVID vaccines “the deadliest vaccine ever made,” canceled approximately $500 million in federal mRNA research funding earlier in the administration’s term. Kennedy’s overhaul of FDA advisory panels prompted sustained criticism from scientists who argued the changes were designed to align federal health oversight with his personal positions rather than clinical evidence. Kennedy did not issue a statement following Tuesday’s mFlusiva approval.
Congress addressed a related piece of the regulatory picture on Thursday. The Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention by a 51-to-44 vote, largely along party lines, giving the agency its first permanent leader in more than a year. Schwartz, a former deputy surgeon general and Navy physician who served during Trump’s first term, inherits the CDC’s role in immunization policy, including its position in the court-frozen ACIP process. She takes the directorship as the United States records its highest measles case count in 35 years.
Moderna’s mRNA ambitions in the United States extend beyond mFlusiva. The European Union approved the company’s combination mRNA flu and COVID vaccine in April 2026. Moderna subsequently withdrew its U.S. application for the combination product despite positive results, without a detailed public explanation. mFlusiva, the single-antigen flu vaccine, was the product Moderna chose to advance through the American regulatory process first.
For adults between 50 and 64, the immediate question this fall is access. The vaccine will be available at pharmacies and doctor’s offices. Whether it costs them anything depends on whether their insurer elects to cover it voluntarily in the absence of an ACIP recommendation, or whether they are willing to pay out of pocket for a shot whose coverage status their insurer considers unresolved. For adults 65 and older, the insurance question is compounded by the accelerated approval designation, which signals the FDA considers evidence for this age group still developing.
The gap between what Tuesday’s approval announced and what most Americans will be able to access this fall remains the defining open question of the mFlusiva story. Bridging it requires a federal court to lift its injunction on the ACIP, a new CDC director to navigate a committee she inherited on her first day, and an insurer community to act voluntarily in the absence of the formal triggers that normally govern coverage decisions. None of those outcomes is guaranteed. None is imminent.
